FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be lowered in patients with kidney disease by preventing them from absorbing phosphorus from food. This study is designed to see what happens to levels of FGF-23 in the blood when patients with chronic kidney disease take medications to prevent phosphorus absorption. Since high levels of FGF-23 have been linked with increased rates of death in patients with advanced kidney disease, controlling the levels may, in the future, be a way to decrease heart disease in patients with kidney disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
18
Daily renvela (800 mg tid with meals) x 12 weeks
1 inert tablet tid x 12 weeks
UCLA
Los Angeles, California, United States
Change in FGF-23 Level
Change in FGF23 value from baseline in response to Renvela at 12 weeks in comparison to placebo.
Time frame: 12 weeks
1,25(OH)2vitamin D Value
Percentage change in 1,25(OH)2vitamin D level from baseline at 12 weeks.
Time frame: 12 week
Serum Phosphate Concentration
Change in serum phosphate at 12 weeks from baseline
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.